Laying the Groundwork for Success in Polycythemia Vera Management

Dr Michael Grunwald discusses practical patient counseling and symptom management strategies that can help support long-term disease control goals among patients with polycythemia vera.

I'd like to welcome you to this session. The title of this activity is “Planning for Success in the Management of Polycythemia Vera With Interferons.” I'm Dr Michael Grunwald with Oncology Learning Network. It's a pleasure to be here today. I work at Atrium Health Levine Cancer Institute and Wake Forest University School of Medicine in Charlotte, North Carolina, where I practice as a hematologist/oncologist. Patient education is an important component of PV management. Clinicians should reinforce that PV is a chronic condition and that treatment decisions should support long-term disease control and risk reduction. Clinicians may wish to discuss that disease control might not be limited to hematocrit alone. White blood cell count has been correlated with thrombotic recurrence. Routine management often includes monitoring of white blood cell counts and consideration of cytoreductive therapy.

We, as providers, can offer practical specific strategies to manage early symptoms that can occur from polycythemia vera itself and/or from interferon therapy to improve the tolerability of treatment. For fatigue, we can focus on sleep hygiene, including avoiding caffeine later in the day, reducing evening bright or blue light exposure, and balancing activity with rest periods to allow for recovery. For fever, myalgias, and arthralgias, we can consider acetaminophen when clinically appropriate. For pruritus or itching, we can recommend taking cooler showers, avoiding hot water, and using fragrance-free products formulated for sensitive skin. We can also consider first-generation antihistamines at bedtime when itching interferes with sleep. For sore throat symptoms, we can suggest non-pharmacologic measures such as hot tea with honey, lozenges, or saltwater gargles. For timing of administration, we can encourage patients to inject at a time that fits their schedules. Some patients may prefer dosing before a period of reduced activity—for example, Friday afternoons for some patients—to allow adequate time for recovery.

For injection site reactions occurring with interferons, we can recommend applying an ice pack after injection and also rotating injection sites to avoid repeated injections in the same area. Clinicians can provide closer follow-up early in therapy to keep patients on treatment and address concerns promptly. Providers should plan for earlier check-ins during the first months of treatment since early adverse events are common and managing them promptly can help patients continue therapy. Providers should also acknowledge that side effects can differ across patients as immune stimulation begins. We can educate patients that dose adjustments and supportive care are part of long-term management. We as clinicians are recommended to set a clear treatment plan at the start that includes strategies to identify and address tolerability issues early along with practical follow-up planning. This can help patients stay on treatment and achieve long-term benefits.

I'd like to thank you very much for your attention. This activity was called “Planning for Success in the Management of Polycythemia Vera With Interferons.” I'd like to encourage you to complete the 1-question quiz now that you have watched this video.